Objective: To evaluate the association between health insurance coverage and disease-modifying therapy (DMT) use for multiple sclerosis (MS).
Results: Of 6,662 respondents included in the analysis, 6,562 (98.5%) had health insurance, but 1,472 (22.1%) reported negative insurance change compared with 12 months earlier. Respondents with private insurance were more likely to report negative insurance change than any other insurance. Among respondents not taking DMTs, 6.1% cited insurance/financial concerns as the sole reason. Of respondents taking DMTs, 24.7% partially or completely relied on support from free/discounted drug programs. Of respondents obtaining DMTs through insurance, 3.3% experienced initial insurance denial of DMT use, 2.3% encountered insurance denial of DMT switches, and 1.6% skipped or split doses because of increased copay. For respondents with relapsing-remitting MS, negative insurance change increased their odds of not taking DMTs (odds ratio [OR] 1.50; 1.16-1.93), using free/discounted drug programs for DMTs (OR 1.89; 1.40-2.57), and encountering insurance challenges (OR 2.48; 1.64-3.76).
Conclusions: Insurance coverage affects DMT use for persons with MS, and use of free/discounted drug programs is substantial and makes economic analysis that ignores these supplements potentially inaccurate. The rising costs of drugs and changing insurance coverage adversely affect access to treatment for persons with MS. Neurology ® 2016;87:365-374 GLOSSARY ACA 5 Patient Protection and Affordable Care Act; CI 5 confidence interval; DMT 5 disease-modifying therapy; MS 5 multiple sclerosis; OR 5 odds ratio; PDDS 5 Patient-Determined Disease Steps; PPMS 5 primary progressive multiple sclerosis; RRMS 5 relapsing-remitting multiple sclerosis.
Health care utilization is high in persons with multiple sclerosis (MS). Newly diagnosed individuals with MS are 3.5 times more likely to be hospitalized and have health care costs 4.7 times higher than healthy individuals. 1 An important component of these costs is the use of diseasemodifying therapies (DMTs). 1 Although the number of DMTs with differing modes of administration and mechanisms of action has increased over time, accessibility of these therapies has become an increasing concern due to their high and rising costs. 2 Health insurance assists with access to health care. Although most individuals with MS have health insurance, 3 17 .8% of participants with MS in a recent study reported that their insurance was worse in 2009 as compared to 12 months earlier. 4 Due to the high cost of DMTs, private insurers and public insurance regulatory bodies often require individuals with MS to meet specific criteria to obtain coverage for these therapies, 5 or require high copays. 6 Such factors may prevent persons with MS and their physicians from making treatment decisions based on best evidence and patient preferences. [7] [8] [9] The effect of health insurance coverage on the treatment choices made by persons with MS is poorly understood, particularly in the United States, where the health care climate has changed since the inception of the Patient Protection and Affordable Care Act (ACA) in 2012. 10 Therefore, we evaluated the association between health insurance coverage and DMT use in a sociodemographically diverse MS population.
METHODS Study population. Participants in the North
American Research Committee on Multiple Sclerosis Registry voluntarily report demographic and clinical information about their MS at enrollment and semiannually thereafter using paper or online questionnaires.
Standard protocol approvals, registrations, and patient consents. Participants agree to the use of their information for research purposes. The registry is approved by the Institutional Review Board at the University of Alabama at Birmingham.
Information collected at enrollment includes sex, date of birth, race (dichotomized as Caucasian/non-Caucasian), marital status (dichotomized as married/not married), current employment status (full-time, part-time, unemployed), annual income (#$30,000 USD, $30,001-$100,000 USD, .$100,000 USD), year of MS onset, age and year of MS diagnosis, type of MS (relapsing-remitting MS [RRMS], primary progressive MS [PPMS], and other), and level of disability reported using Patient-Determined Disease Steps (PDDS). The PDDS is an ordinal rating scale derived from Disease Steps, which ranges from 0 (no disability) to 8 (bedridden), 11 and correlates highly with a physician-scored Expanded Disability Status Scale. 12, 13 Each semiannual survey reassesses level of disability; captures whether any DMTs were used in the last 6 months (yes/no) and the names of the DMT used; and updates sociodemographic information including marital status, employment status, and health insurance coverage (yes/no) including type (private, public, supplemental, and other).
In the fall 2014 update survey, participants also reported whether health insurance coverage had been available for the entire 6 months preceding the survey (yes/no). They reported perceived change in their insurance compared with 12 months ago using a question adapted from Pozniak et al. 4 with 4 response options: much better, somewhat better, remained unchanged, somewhat worse. Participants reported the influence of their insurance and financial situation on DMT choices in the last 12 months using a 17-option question (table 1) . Analysis. Only respondents who completed all insurance-related questions were included in the analysis. We divided the respondents into 2 categories based on their answers to the 17option question (table 1, figure 1): (1) those who did not take or stopped taking DMTs in the last 12 months (checked any of options 1-4, or 17) (referred to as not taking DMT) and (2) those who took DMTs in the last 12 months (checked any of options 5-16) (referred to as taking DMT). For respondents who fell into both categories, we used their response to a separate question on DMT use in the last 6 months to ascertain final category placement where those reporting DMT use in the last 6 months were labeled as taking DMT and all others as not taking DMT.
Within the not taking DMT category, we divided respondents into 2 groups by their reasons for not taking DMTs: (1) those who did not take DMTs by personal choice or physician Neurology 87 July 26, 2016 367 recommendation (options 1 and 4) and (2) those citing insurance or financial reasons (options 2, 3, and 17). It was possible that some respondents decided not to take DMTs for multiple reasons, thus we allowed respondents to fall into both groups. Within the taking DMT category, we divided respondents into 3 groups according to the financial resources used to pay for DMTs: (1) self-pay only (no insurance); (2) free or discounted drug programs; and (3) insurance. It was reasonable that some respondents obtained DMTs using multiple resources concurrently, thus overlap between groups 1 and 2 or groups 2 and 3 was allowed. However, overlap between groups 1 and 3 was not allowed; those who fell into both groups 1 and 3 were assigned into group 3 only. Due to the small number of respondents in group 1 (n 5 34), only respondents in groups 2 and 3 were used for statistical inference.
We partitioned respondents who obtained DMTs through insurance into 6 groups by whether or not they encountered any challenges from their insurance for DMT use: (1) no challenges from insurance for DMT use (options 5-7, 11, 12); (2) initial insurance denial of DMT (option 10); (3) insurance denial of DMT switch (option 13); (4) DMT switch due to insurance change (option 14); (5) DMT change due to increased copay (option 15); and (6) skipping or splitting DMTs due to increased copay (option 16). Belonging to multiple groups was allowed. Respondents with any insurance challenge were grouped together and compared to those without insurance challenge. We grouped respondents' health insurance into 4 mutually exclusive groups: only public, only private, public and private, and public1 (public insurance 1 supplemental/other insurance).
We characterized the study cohort using descriptive statistics and used Pearson x 2 to compare the proportions of categorical variables, analysis of variance to test normally distributed continuous variables, and nonparametric Wilcoxon or Kruskal to test non-normally distributed continuous variables or ordinal variables. We dichotomized respondents' insurance change compared with 12 months ago as negative insurance change (somewhat worse) and stable insurance (remained unchanged, somewhat better, and much better). The association between negative insurance change and (1) type of insurance, (2) DMT use, (3) use of free or discounted drug programs, or (4) insurance challenges was investigated using multivariable logistic regression analyses 14 adjusting for potential confounders including age at the time of survey, PDDS, disease duration, annual income, marital status, disability status, and employment status in the last 6 months and for type of insurance (for outcomes 2, 3, and 4). We initially conducted analyses for all respondents and then repeated our analyses limited to RRMS respondents since the clinical trials leading to DMT approval only enrolled persons with RRMS. 15 All p values were based on 2-sided tests and values ,0.05 were considered significant. All analyses were conducted using SAS 9.4 (SAS Institute, Cary, NC).
RESULTS
Of the 12,492 active participants invited to complete the fall 2014 update survey, 7,601 (60.9%) completed the survey, of whom 6,662 (87.6%) completed all insurance-related questions and were included in this study. As compared to respondents, nonrespondents were younger (table e-1 on the Neurology ® Web site at Neurology.org). Respondents included in the study were more likely to be female, to be younger at the time of survey, to have a higher income and shorter disease duration, and to have RRMS compared to those not included (table e-1). Negative insurance change and DMT use. Among all respondents, 4,610 (69.2%) took DMTs ( figure 1A) , as did 3,072 (80.6%) of the RRMS respondents (figure e-1a). Respondents not taking DMTs were more likely to be older, unemployed, and male, with lower incomes, longer disease durations, and more severe disability, and to have PPMS compared to those taking DMTs (table 2) . Similar findings were observed among those with RRMS (table 2). The association between negative insurance change and DMT use was not statistically significant among the 6,662 respondents, but was among the RRMS respondents (table 3) . After adjustment, the odds of not taking DMTs for RRMS respondents with negative insurance change were higher than for those with stable insurance, and were higher for those with only public insurance compared to those with only private insurance (table 3) .
Reasons for not taking DMT. Among respondents not taking DMTs, most did not take DMTs by personal choice, physician recommendation, or both. However, 6.1% were unable to take DMTs solely due to insurance or financial reasons ( figure 1A) . This increased to 9.2% when restricted to RRMS (figure e-1a). As compared to respondents who did not take DMTs by choice or physician recommendation, those who did not take DMTs for insurance reasons were more likely to be women, younger at the time of survey, and employed, with lower incomes, to have experienced an income change in the prior 6 months, to have RRMS, and to report a negative insurance change (table 4) . When analyses were restricted to RRMS, similar findings were observed (table e-2).
Negative insurance change and the use of free or discounted drug programs. Among respondents taking DMTs, about three-quarters obtained DMTs solely through insurance, while 15.1% completely and 9.6% partially used free or discounted drug programs ( figure 1A) . As compared to those who obtained DMTs through insurance, those who utilized free or discounted drug programs were more likely to be female, younger at the time of survey, and not married, and to report negative insurance change, to have shorter disease durations, and to experience RRMS (table 4) . After adjustment, the odds of using free or discounted drug programs were higher for those with negative insurance change than those with stable insurance and for those with public1 insurance compared to those with only private or private and public (table 3) . When restricted to RRMS respondents, the findings were similar (tables 3 and e-2).
Negative insurance change and ongoing DMT use.
Although most of the 3,878 respondents who obtained DMTs through insurance did not report any insurance challenges related to their DMT use in the last 12 months, insurance challenges were not rare. For example, 125 (3.3%) respondents reported that their insurance initially denied their DMT use but their physicians were able to convince their insurance provider to pay, 88 (2.3%) reported that their insurance provider denied the request to switch DMTs, and 61 (1.6%) had to skip or split doses due to increased copay ( figure 1B) . Some respondents encountered insurance challenges during only part of the 12-month period. Overall, 303 (7.8%) respondents reported at least one insurance challenge. Compared to respondents who never encountered insurance challenges for DMT use, those with insurance challenges were younger at the time of survey and more likely to have income change, negative insurance change, lower incomes, and shorter disease durations (table 4) . When restricted to RRMS respondents, the only persistent difference was in the proportion with negative insurance change (19.8% for those without insurance challenges vs 48.2% for those with). After adjustment, the odds of encountering insurance challenges for DMT use for respondents with negative insurance change were higher than those with stable insurance regardless of MS type (table 3) . DISCUSSION In this study of 6,662 persons with MS in the United States, we found that although most individuals had health insurance, over 20% reported that their insurance coverage had worsened over the last 12 months. This worsening may underestimate the proportion with coverage changes, since changes in insurance coverage often occur annually and our survey would capture some participants before an impending change is recognized. Among respondents who did not take DMTs, over 6% reported the sole reason to be financial or insurance concerns. Of respondents taking DMTs, nearly 25% relied on at least partial support from free or discounted drug programs. Of respondents who obtained DMTs through insurance, more than 3% experienced initial insurance denial of DMT use, over 2% encountered an insurance denial on DMT switch, and nearly 2% had to skip or split doses because of increased copays.
We employed a similar question to another study, and our estimate of the proportion of respondents who reported that their insurance coverage was worse is about 4% higher than reported previously. 4 The slight difference may reflect differences in study cohorts or time periods. Our study had nearly 3 times as many respondents and our respondents had longer disease duration and lower annual income. The study by Pozniak et al. 4 was conducted 5 years earlier than ours, which was conducted over 6 months after the ACA took effect. 10 Respondents with private insurance were more likely to report negative insurance change. Financial burden and lack of insurance coverage of DMT use directly affected access to any DMT for a large number of respondents and posed challenges for respondents and their physicians with respect to the choice of DMT. As expected, negative insurance change affected persons with RRMS more than those without RRMS since the available DMTs mainly target RRMS. These negative effects likely reflect the dramatically increased cost of DMTs and the response to those high costs by insurance carriers. 2 However, the crosssectional study design prevents us from confirming the conjecture that initial denial of coverage for DMTs occurred more frequently now than previously for new and established patients. 2 One encouraging observation in our study is that respondents who encountered initial insurance denials of DMTs also reported that their doctors usually were able to obtain coverage by the insurance carriers for the desired treatment. This highlights the important role physicians play in maintaining patient access to DMTs. 2 It is uncertain whether the extensive use of free or discounted drug programs reflects that a preferred DMT was not covered by insurance or whether copays were too high, but suggests an important gap between health insurance needs and current coverage. While negative insurance changes may explain the gap for some individuals, the recognized rise in the cost of DMTs is likely to be another substantial contributing factor. 2 If the costs of DMTs continue to rise as they have over the last 5 years, we can expect that they will become unattainable for many individuals with MS. Further, economic studies that fail to incorporate information on subsidized drugs may come to inaccurate conclusions when doing costeffectiveness analyses.
We found that the financial burden of DMTs also reduced the ability of persons with MS to adhere to therapy as manifest by skipping doses, further reducing the benefit from these therapies. Nonadherence increases the risk for MS-related hospitalization, relapse, and medical costs. 16 Other authors have reported that over 40% of persons with MS were not adherent to DMTs, with barriers including depression, cognitive impairment, perceived lack of efficacy, adverse events, inconvenience of injection, and needle phobia. 16, 17 The cost of medications contributes importantly to nonadherence, 18, 19 and we have shown that this is a specific concern in the MS population, which may worsen as the costs of DMTs rise. Future studies should seek to understand the relative importance of, and interplay between, all of these factors in nonadherence and how they vary across health systems.
The potential limitations of this study include self-report bias, recall bias, and the selection biases inherent in a self-report registry. 20 Additionally, the dynamic nature of insurance and the limitation of cross-sectional studies make it difficult to investigate the reasons for insurance challenges and for the extensive use of free or discounted drug programs. We do not know whether participants considered copay support to be a form of discounted medication, thus we may have underestimated the degree of financial support provided by pharmaceutical companies. We focused on access to DMTs as they are very costly, but access to symptomatic therapies, durable medical equipment, and other health services are also relevant, as is the cost of health insurance itself. Nonetheless, the suggestion of an increasing trend implied by the large percentage of respondents who reported negative insurance change is important.
Although more DMTs have emerged over the last few years, the costs of these therapies are a substantial impediment to their use. 2 As DMTs become more costly, given the poor quality of some insurance coverage, it will be increasingly difficult for persons with MS to avail themselves of this treatment option without additional supports such as free or discounted drug programs. Among those with RRMS, young women and individuals with lower incomes are less likely to use these therapies. Action is needed to ensure that all individuals eligible for DMT, including groups for which therapies are newly emerging such as PPMS, are able to benefit from these therapies if they and their physicians deem it to be the best course of action.
